Clinical Trials Directory

Trials / Completed

CompletedNCT00627705

A Study of N-Acetyl Cysteine in Children With Autism

Double-blind , Randomized, Placebo Controlled Study of N-Acetyl Cysteine in Autism.

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
43 (actual)
Sponsor
Stanford University · Academic / Other
Sex
All
Age
3 Years – 12 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study is to test the tolerability and efficacy of N-Acetyl Cysteine (NAC) in children with Autism. NAC is a compound that increases the levels of Glutathione, the body's main antioxidant. Glutathione is a compound in the blood that is part of a natural defense system (the antioxidant system). Anti-oxidants protect the body from damage caused by internal toxins called "free radicals." It is possible that children with Autism tend to have lower levels of glutathione, an important compound in our bodies that helps combat the effects of toxic free radicals. We hope that by studying the antioxidant system in more detail, we will increase our understanding of the reasons why people develop Autism so that we can design better ways to treat individuals with this condition. This study is meant to test the safety tolerability of NAC and its effectiveness in the treatment of behavioral difficulties in children with autism. It will also examine the possible benefit of this agent in improving the core deficits in autism such as social deficits.

Conditions

Interventions

TypeNameDescription
DRUGN-Acetyl CysteinePhase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks Entire intervention lasts for 12 weeks (drug administration is continuous).
OTHERPlacebo - sugar pillPhase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks Entire intervention lasts for 12 weeks (drug administration is continuous).

Timeline

Start date
2008-02-01
Primary completion
2010-09-01
Completion
2010-09-01
First posted
2008-03-03
Last updated
2017-05-18
Results posted
2017-05-18

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00627705. Inclusion in this directory is not an endorsement.